Clinical trial · Interventional
Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.
Whole-body Diffusion-weighted Magnetic Resonance Imaging and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence Following Surgery or Systemic Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with locally advanced melanoma are at high risk for recurrence following surgical treatment. More patients with stage IV melanoma remain in complete remission following systemic therapy. No standards have been established for the surveillance of patients at high risk for recurrence. Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis of blood are innovative imaging and laboratory investigations that may be of benefit for early detection of recurrence in this patient population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| follow up DW MRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- stage IV melanoma CR>3years
- description
- Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
- interventionNames
- Other: follow up DW MRI
- type
- EXPERIMENTAL
- label
- Stage III Melanoma
- description
- AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
- interventionNames
- Other: follow up DW MRI
Primary outcomes (1)
- measure
- explorative evaluation of the use of DWMRI in the follow-up of high risk melanoma patients
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed malignant melanoma; * AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging * Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging Exclusion Criteria: * Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\< 6weken) * Claustrophobia * Metallic devices implanted such as hip prostheses, since this can alter the imaging quality
References
Publications (0)
Data not yet available